Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apremilast.

Literature DB >> 25477601

Apremilast.

Dennis J Cada¹, Kyle Ingram², Danial E Baker³.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The September 2014 monograph topics are tedizolid phosphate, ceritinib, omega-3-carboxylic acids, umeclidinium bromide inhalation powder, and siltuximab. The DUE/MUE is on avoidance of insulin use errors.

Entities: Chemical

Year: 2014 PMID： 25477601 PMCID： PMC4252204 DOI： 10.1310/hpj4908-752

Source DB: PubMed Journal: Hosp Pharm ISSN： 0018-5787

12 in total

Review 1. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

Authors: Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Mark Lebwohl; Craig L Leonardi; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Caitriona Ryan; Reva Bhushan
Journal: J Am Acad Dermatol Date: 2011-02-08 Impact factor: 11.527

2. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors: Georg Schett; Jurgen Wollenhaupt; Kim Papp; Rik Joos; Jude F Rodrigues; Adele R Vessey; ChiaChi Hu; Randall Stevens; Kurt L de Vlam
Journal: Arthritis Rheum Date: 2012-10

3. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Authors: Kim Papp; Jennifer C Cather; Les Rosoph; Howard Sofen; Richard G Langley; Robert T Matheson; ChiaChi Hu; Robert M Day
Journal: Lancet Date: 2012-06-29 Impact factor: 79.321

4. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

Authors: Peter Schafer
Journal: Biochem Pharmacol Date: 2012-01-10 Impact factor: 5.858

5. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

Authors: K A Papp; R Kaufmann; D Thaçi; C Hu; D Sutherland; P Rohane
Journal: J Eur Acad Dermatol Venereol Date: 2012-10-03 Impact factor: 6.166

6. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors: P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal: Br J Pharmacol Date: 2009-12-24 Impact factor: 8.739

7. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.

Authors: Ejaz Pathan; Sonya Abraham; Elizabeth Van Rossen; Robin Withrington; Andrew Keat; Peter J Charles; Erin Paterson; Muslima Chowdhury; Catherine McClinton; Peter C Taylor
Journal: Ann Rheum Dis Date: 2012-09-14 Impact factor: 19.103

8. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

Authors: A B Gottlieb; B Strober; J G Krueger; P Rohane; J B Zeldis; C C Hu; C Kipnis
Journal: Curr Med Res Opin Date: 2008-04-16 Impact factor: 2.580

9. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

Authors: Fiona E McCann; Andrew C Palfreeman; Melanie Andrews; Dany P Perocheau; Julia J Inglis; Peter Schafer; Marc Feldmann; Richard O Williams; Fionula M Brennan
Journal: Arthritis Res Ther Date: 2010-06-02 Impact factor: 5.156

10. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors: Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal: Ann Rheum Dis Date: 2014-03-04 Impact factor: 19.103

5 in total

Apremilast.

Review 1. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

2. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

3. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

4. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

5. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

6. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

7. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.

8. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

9. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

10. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Review 1. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

2. Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.

Review 3. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.

Review 4. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.

5. Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice.